These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. O-(2-18F-fluoroethyl)-L-tyrosine PET predicts failure of antiangiogenic treatment in patients with recurrent high-grade glioma. Hutterer M; Nowosielski M; Putzer D; Waitz D; Tinkhauser G; Kostron H; Muigg A; Virgolini IJ; Staffen W; Trinka E; Gotwald T; Jacobs AH; Stockhammer G J Nucl Med; 2011 Jun; 52(6):856-64. PubMed ID: 21622893 [TBL] [Abstract][Full Text] [Related]
5. Prognostic Value of O-(2-[18F]-Fluoroethyl)-L-Tyrosine-Positron Emission Tomography Imaging for Histopathologic Characteristics and Progression-Free Survival in Patients with Low-Grade Glioma. Bette S; Gempt J; Delbridge C; Kirschke JS; Schlegel J; Foerster S; Huber T; Pyka T; Zimmer C; Meyer B; Ringel F World Neurosurg; 2016 May; 89():230-9. PubMed ID: 26855307 [TBL] [Abstract][Full Text] [Related]
6. O-(2-[(18)F]fluoroethyl)-L-tyrosine uptake is an independent prognostic determinant in patients with glioma referred for radiation therapy. Sweeney R; Polat B; Samnick S; Reiners C; Flentje M; Verburg FA Ann Nucl Med; 2014 Feb; 28(2):154-62. PubMed ID: 24272067 [TBL] [Abstract][Full Text] [Related]
7. Prognostic value of 18F-fluoroethyl-L-tyrosine PET and MRI in small nonspecific incidental brain lesions. Floeth FW; Sabel M; Stoffels G; Pauleit D; Hamacher K; Steiger HJ; Langen KJ J Nucl Med; 2008 May; 49(5):730-7. PubMed ID: 18413396 [TBL] [Abstract][Full Text] [Related]
8. Role of O-(2-18F-fluoroethyl)-L-tyrosine PET as a diagnostic tool for detection of malignant progression in patients with low-grade glioma. Galldiks N; Stoffels G; Ruge MI; Rapp M; Sabel M; Reifenberger G; Erdem Z; Shah NJ; Fink GR; Coenen HH; Langen KJ J Nucl Med; 2013 Dec; 54(12):2046-54. PubMed ID: 24159047 [TBL] [Abstract][Full Text] [Related]
9. An interindividual comparison of O-(2-[18F]fluoroethyl)-L-tyrosine (FET)- and L-[methyl-11C]methionine (MET)-PET in patients with brain gliomas and metastases. Grosu AL; Astner ST; Riedel E; Nieder C; Wiedenmann N; Heinemann F; Schwaiger M; Molls M; Wester HJ; Weber WA Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):1049-58. PubMed ID: 21570201 [TBL] [Abstract][Full Text] [Related]
11. The use of dynamic O-(2-18F-fluoroethyl)-l-tyrosine PET in the diagnosis of patients with progressive and recurrent glioma. Galldiks N; Stoffels G; Filss C; Rapp M; Blau T; Tscherpel C; Ceccon G; Dunkl V; Weinzierl M; Stoffel M; Sabel M; Fink GR; Shah NJ; Langen KJ Neuro Oncol; 2015 Sep; 17(9):1293-300. PubMed ID: 26008606 [TBL] [Abstract][Full Text] [Related]
12. Magnetic resonance imaging in central nervous system vasculitis in a patient affected by crioglobulin-negative hepatitis C virus infection: A likely correlation. Squarza S; Galli A; Cariati M; Alberici F; Bertolini V; Frediani F; Uggetti C Neuroradiol J; 2018 Apr; 31(2):193-195. PubMed ID: 28735554 [TBL] [Abstract][Full Text] [Related]
13. Metabolic imaging of cerebral gliomas: spatial correlation of changes in O-(2-18F-fluoroethyl)-L-tyrosine PET and proton magnetic resonance spectroscopic imaging. Stadlbauer A; Prante O; Nimsky C; Salomonowitz E; Buchfelder M; Kuwert T; Linke R; Ganslandt O J Nucl Med; 2008 May; 49(5):721-9. PubMed ID: 18413402 [TBL] [Abstract][Full Text] [Related]
15. Comparison of O-(2-18F-fluoroethyl)-L-tyrosine PET and 3-123I-iodo-alpha-methyl-L-tyrosine SPECT in brain tumors. Pauleit D; Floeth F; Tellmann L; Hamacher K; Hautzel H; Müller HW; Coenen HH; Langen KJ J Nucl Med; 2004 Mar; 45(3):374-81. PubMed ID: 15001676 [TBL] [Abstract][Full Text] [Related]
16. Comparison of 18F-FET PET and perfusion-weighted MR imaging: a PET/MR imaging hybrid study in patients with brain tumors. Filss CP; Galldiks N; Stoffels G; Sabel M; Wittsack HJ; Turowski B; Antoch G; Zhang K; Fink GR; Coenen HH; Shah NJ; Herzog H; Langen KJ J Nucl Med; 2014 Apr; 55(4):540-5. PubMed ID: 24578243 [TBL] [Abstract][Full Text] [Related]
17. Diagnosis of pseudoprogression in patients with glioblastoma using O-(2-[18F]fluoroethyl)-L-tyrosine PET. Galldiks N; Dunkl V; Stoffels G; Hutterer M; Rapp M; Sabel M; Reifenberger G; Kebir S; Dorn F; Blau T; Herrlinger U; Hau P; Ruge MI; Kocher M; Goldbrunner R; Fink GR; Drzezga A; Schmidt M; Langen KJ Eur J Nucl Med Mol Imaging; 2015 Apr; 42(5):685-95. PubMed ID: 25411133 [TBL] [Abstract][Full Text] [Related]
18. Primary central nervous system vasculitis with prominent leptomeningeal enhancement: a subset with a benign outcome. Salvarani C; Brown RD; Calamia KT; Christianson TJ; Huston J; Meschia JF; Giannini C; Miller DV; Hunder GG Arthritis Rheum; 2008 Feb; 58(2):595-603. PubMed ID: 18240248 [TBL] [Abstract][Full Text] [Related]
19. Value of O-(2-[18F]fluoroethyl)- L-tyrosine PET for the diagnosis of recurrent glioma. Pöpperl G; Götz C; Rachinger W; Gildehaus FJ; Tonn JC; Tatsch K Eur J Nucl Med Mol Imaging; 2004 Nov; 31(11):1464-70. PubMed ID: 15248032 [TBL] [Abstract][Full Text] [Related]
20. Spontaneously changing MRI findings of primary central nervous system vasculitis: A case report. Takatsu H; Komatsu T; Fukasawa N; Fukuda T; Iguchi Y J Clin Neurosci; 2021 Jan; 83():125-127. PubMed ID: 33246904 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]